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Japanese Encephalitis Vaccines
Recommendations of the Advisory Committee on Immunization Practices 
(ACIP)
Prepared by
Marc Fischer, MD, Nicole Lindsey, MS, J. Erin Staples, MD, PhD, Susan Hills, MBBS
Division of Vector-Borne Infectious Diseases, National Center for Emerging and Zoonotic Infectious Diseases (proposed), CDC
Summary
This report updates the 1993 recommendations by CDC’s Advisory Committee on Immunization Practices (ACIP) regarding 
the prevention of Japanese encephalitis (JE) among travelers (CDC. Inactivated Japanese encephalitis virus vaccine: recommenda-
tions of the Advisory Committee on Immunization Practices [ACIP]. MMWR 1993;42[No. RR-1]). This report summarizes the 
epidemiology of JE, describes the two JE vaccines that are licensed in the United States, and provides recommendations for their 
use among travelers and laboratory workers.
JE virus (JEV), a mosquito-borne flavivirus, is the most common vaccine-preventable cause of encephalitis in Asia. JE occurs 
throughout most of Asia and parts of the western Pacific. Among an estimated 35,000–50,000 annual cases, 20%–30% of 
patients die, and 30%–50% of survivors have neurologic or psychiatric sequelae. No treatment exists. For most travelers to Asia, 
the risk for JE is very low but varies on the basis of destination, duration, season, and activities. 
JE vaccine is recommended for travelers who plan to spend a month or longer in endemic areas during the JEV transmission 
season and for laboratory workers with a potential for exposure to infectious JEV. JE vaccine should be considered for 1) short-
term (<1 month) travelers to endemic areas during the JEV transmission season if they plan to travel outside of an urban area and 
will have an increased risk for JEV exposure; 2) travelers to an area with an ongoing JE outbreak; and 3) travelers to endemic 
areas who are uncertain of specific destinations, activities, or duration of travel. JE vaccine is not recommended for short-term 
travelers whose visit will be restricted to urban areas or times outside of a well-defined JEV transmission season.
 Two JE vaccines are licensed in the United States. An inactivated mouse brain–derived JE vaccine (JE-VAX [JE-MB]) has been 
licensed since 1992 to prevent JE in persons aged ≥1 year traveling to JE-endemic countries. Supplies of this vaccine are limited 
because production has ceased. In March 2009, an inactivated Vero cell culture-derived vaccine (IXIARO [JE-VC]) was licensed 
for use in persons aged ≥17 years. JE-MB is the only JE vaccine available for use in children aged 1−16 years, and remaining 
supplies will be reserved for use in this group.
Introduction
Japanese encephalitis virus (JEV), a mosquito-borne flavivi-
rus, is the most common vaccine-preventable cause of encepha-
litis in Asia (1,2). Japanese encephalitis (JE) occurs throughout 
most of Asia and parts of the western Pacific (1,3). Among 
an estimated 35,000–50,000 annual cases, approximately 
20%–30% of patients die, and 30%–50% of survivors have 
neurologic or psychiatric sequelae (4,5). In endemic countries, 
JE is primarily a disease of children. However, travel-associated 
JE, although rare, can occur among persons of any age (6–9). 
For most travelers to Asia, the risk for JE is very low but varies 
based on destination, duration, season, and activities (9,10).
JEV is transmitted in an enzootic cycle between mosquitoes 
and amplifying vertebrate hosts, primarily pigs and wading 
birds (11,12). JEV is transmitted to humans through the 
bite of an infected mosquito, but disease develops in <1% of 
infected persons. JEV transmission occurs primarily in rural 
agricultural areas. In most temperate areas of Asia, JEV trans-
mission is seasonal, and substantial epidemics can occur. In 
the subtropics and tropics, transmission can occur year-round, 
often intensifying during the rainy season.
This report provides recommendations for use of the two 
JE vaccines licensed in the United States for prevention of 
JE among travelers and laboratory workers. An inactivated 
mouse brain–derived JE vaccine (JE-MB) has been available 
since 1992 for use in travelers aged ≥1 year (13). In March 
2009, the Food and Drug Administration (FDA) approved a 
This report originated in the National Center for Emerging and 
Zoonotic Infectious Diseases (proposed), Thomas Hearn, PhD, Acting 
Director, and the Division of Vector-Borne Infectious Diseases, Lyle 
Petersen, MD, Director.
Corresponding preparer: Marc Fischer, MD, Division of Vector-
Borne Infectious Diseases, National Center for Emerging and Zoonotic 
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Fort Collins, CO 80521. Telephone: 970-221-6489; Fax: 970-266-
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new inactivated Vero cell culture-derived JE vaccine (JE-VC) 
for use in persons aged ≥17 years (14).
Methods
The Advisory Committee on Immunization Practices (ACIP) 
JE vaccine workgroup* first met in October 2006 to review 
available information on the risk for JE for travelers, begin revis-
ing recommendations for the use of the available vaccine, and 
develop recommendations for the use of a new vaccine. In addi-
tion to ACIP members, the workgroup included participants 
from CDC, FDA, National Institutes of Health, Department 
of Defense, Public Health Agency of Canada, European Centre 
for Disease Prevention and Control, American Academy of 
Pediatrics, International Society of Travel Medicine, American 
Society of Tropical Medicine and Hygiene, PATH JE Project, 
American Osteopathic Association, National Association of 
Pediatric Nurse Practitioners, Association of Immunization 
Managers, Washington State Department of Health, and the 
University of Liverpool. Workgroup members included persons 
with expertise in JE, infectious diseases, travel medicine, public 
health, biostatistics, immunization safety, and vaccine policy.
The workgroup reviewed JE epidemiology, incidence of and 
risk factors for travel-associated JE disease, measures available 
to prevent JE disease, and the efficacy, immunogenicity, safety, 
cost-effectiveness, and availability of JE vaccine. Primary 
sources were published, peer-reviewed studies; however, 
unpublished data also were considered. Articles were identified 
through searches of the PubMed, Global Health, and EMBASE 
databases, review of relevant bibliographies, and consultation 
with subject-matter experts.
The workgroup held regular conference calls and met three 
times. Recommendation options were developed and discussed. 
When definitive research evidence was lacking, the recom-
mendations incorporated expert opinion of the workgroup 
members. The workgroup presented progress reports and 
preliminary recommendations to ACIP during its February 
2008 and October 2008 meetings. Proposed recommendations 
and a draft statement were presented to ACIP and approved 
at the June 2009 meeting.
ACIP will review additional data as these are made available, 
particularly regarding any adverse events following receipt of 
JE-VC that are reported during postmarketing surveillance 
studies. Recommendations will be updated as needed.
Background
JEV transmission
JEV is a single-stranded RNA virus that belongs to the genus 
Flavivirus and is closely related to West Nile, St. Louis encepha-
litis, yellow fever, and dengue viruses (15,16). Four genotypes 
of JEV have been identified (17). JEV is an arthropod-borne 
virus (arbovirus) that is transmitted in an enzootic cycle 
between mosquitoes and amplifying vertebrate hosts, primar-
ily pigs and wading birds (Figure 1) (12,18–22). Because of 
rapid population turnover with a large number of susceptible 
offspring and the development of high-titered JEV viremias, 
domestic pigs are the most important source of infection for 
mosquitoes that transmit JEV to humans (11,22–26).
JEV is transmitted to humans through the bites of infected 
mosquitoes. Humans usually do not develop a level or duration 
of viremia sufficient to infect mosquitoes (12,27). Therefore, 
humans are dead-end hosts, and human JE cases imported 
into nonendemic areas represent a minimal risk for subsequent 
transmission of the virus. Direct person-to-person spread of 
JEV does not occur except rarely through intrauterine trans-
mission (1,28,29). On the basis of experience with similar 
flaviviruses, blood transfusion and organ transplantation also 
are considered potential modes of JEV transmission (30,31).
Culex mosquitoes, especially Cx. tritaeniorhynchus, are the 
principal vector for both zoonotic and human JEV transmis-
sion throughout Asia (11,12,18,21,32–39). Cx. tritaenio-
rhynchus is an evening- and nighttime-biting mosquito that 
feeds preferentially on large domestic animals and birds and 
only infrequently on humans. Cx. tritaeniorhynchus feed most 
often in the outdoors, with peak feeding activity occurring after 
sunset (20). Larvae are found in flooded rice fields, marshes, 
and other small stagnant collections of water (37,38). In tem-
perate zones, this vector is present in greatest density from 
June through November; it is inactive during winter months 
(20,40,41). In certain parts of Asia, other mosquito species 
also might be important JEV vectors (12,36,38,40).
Epidemiology of JE
Geographic Distribution and Spread
JE occurs throughout most of Asia and parts of the western 
Pacific (Figure 2). During the first half of the 20th century, 
the disease was recognized principally in temperate areas of 
Asia including Japan, Korea, Taiwan, and mainland China 
(42–50). Over the past few decades, the disease appears to 
have spread south and west with increased JEV transmission 
reported in Southeast Asia, India, Bangladesh, Sri Lanka, and 
Nepal (35,44,48,51–62). In the 1990s, JEV spread east and 
* A list of the members appears on page 27 of this report.
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was recognized for the first time in Saipan and then Australia, 
initially in the outer Torres Strait islands and subsequently on 
the northern mainland (63–65). The reasons for this increased 
geographic distribution are uncertain but might include popu-
lation shifts or changes in climate, ecology, agricultural prac-
tices, animal husbandry, or migratory bird patterns (38,48,65). 
These factors could contribute to further spread, including 
potentially beyond Asia and the western Pacific.
Incidence and Burden of Disease
In the early 1970s, more than 100,000 cases of JE were 
reported each year, with the vast majority from China (49,66). 
Because of vaccine use, increased urbanization, changes in agri-
cultural practices, and mosquito control, annual JE case counts 
have declined substantially during the past 30 years (66). Up 
to 30,000 cases of JE still are reported each year (5). However, 
as a result of poor diagnostic and surveillance capacity in many 
endemic countries, this number likely represents an underesti-
mate of the true burden of disease (5,66). Among children in 
endemic countries, the incidence of laboratory-confirmed JE 
varies widely from year to year and area to area (range: 5–50 
cases per 100,000 children per year) (12,41,42,47,66–70).
Ecologic and Seasonal Patterns
The risk for JE varies by local ecology and season. JEV 
transmission occurs primarily in rural agricultural areas, often 
associated with rice production and flooding irrigation, where 
large numbers of vector mosquitoes breed in close proxim-
ity to animal reservoirs (18,21). In some areas of Asia, these 
ecologic conditions might occur near, or rarely within, urban 
centers (71). 
In temperate areas of Asia, JEV transmission is seasonal, 
and human disease usually peaks in the summer and fall 
(41,42,46,47,50,60,62,72). Seasonal epidemics can be explo-
sive, with thousands of JE cases occurring over a period of 
several months. In the subtropics and tropics, transmission can 
occur year-round, often with a peak during the rainy season 
(48,51,56,70).
Age-Specific Patterns
In endemic areas, JE is primarily a disease of childhood, 
with the vast majority of cases occurring among children aged 
<15 years (41,46,47,50–52,60,62,70,73–75). However, in 
areas with childhood JE immunization programs, the overall 
incidence of JE decreases, and similar numbers of cases are 
observed among children and adults (42,43,50). In both Japan 
in 2002 and northern China in 2006, outbreaks were reported 
in which the majority of cases occurred among older adults 
FIGURE 1. Transmission cycle of Japanese encephalitis virus (JEV)*
*JEV is transmitted in an enzootic cycle between Culex mosquitoes and amplifying vertebrate hosts, primarily pigs and wading birds. Humans are a dead-
end host in the JEV transmission cycle with brief and low levels of viremia.  Humans play no role in the maintenance or amplification of JEV, and the virus 
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(76,77). Because unvaccinated travelers from nonendemic 
countries usually are immunologically naïve, travel-associated 
JE can occur in persons of any age.
Clinical Manifestations and Diagnosis
Signs and Symptoms
The majority of human infections with JEV are asymp-
tomatic; <1% of people infected with JEV develop clinical 
disease (12,67,68,73,77–79). Acute encephalitis is the most 
commonly identified clinical syndrome with JEV infection 
(12,72,80–82). Milder forms of disease (e.g., aseptic meningitis 
or undifferentiated febrile illness) also can occur but have been 
reported more commonly among adults (72,83,84).
Among patients who develop clinical symptoms, the incu-
bation period is 5–15 days. Illness usually begins with acute 
onset of fever, headache, and vomiting (55,85,86). Mental 
status changes, focal neurologic deficits, generalized weakness, 
and movement disorders might occur over the next few days 
(55,82,85–90). Seizures are common, especially among chil-
dren (85–87,90–92). The classical description of JE includes 
a parkinsonian syndrome with mask-like facies, tremor, 
cogwheel rigidity, and choreoathetoid movements (82,93). 
Acute flaccid paralysis, with clinical and pathological features 
































SOURCE: Fischer M, Griggs A, Staples J. Japanese encephalitis. In: Brunette G, ed. Health information for international travel 2010. Atlanta: US Department 
of Health and Human Services, Public Health Service; 2009:74–81. 
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similar to poliomyelitis, also has been associated with JEV 
infection (93,94). Status epilepticus, brain hypoxia, increased 
intracranial pressure, brainstem herniation, and aspiration 
pneumonia are the most common complications associated 
with poor outcome and death (82,85,91,95).
Although information on the burden of JEV infection in 
pregnancy is limited, miscarriages and an intrauterine infec-
tion following maternal JE have been reported. In India, four 
miscarriages were reported among nine infected pregnant 
women; all of the women who miscarried were in the first or 
second trimester of pregnancy (28,29). JEV was isolated in 
one of the four aborted fetuses, suggesting that intrauterine 
transmission of JEV can occur (28).
Clinical Laboratory Findings and 
neuroimaging
Clinical laboratory findings with JE are nonspecific 
and might include moderately elevated white blood cell 
count, mild anemia, and hyponatremia (72,82,85,86,90). 
Thrombocytopenia and elevated hepatic enzymes have 
been noted (86). Cerebrospinal fluid (CSF) usually shows 
a lymphocytic pleocytosis with moderately elevated protein 
(52,55,72,74,82,85,87,90).
Magnetic resonance imaging (MRI) of the brain is better 
than computed tomography (CT) for detecting JEV associated 
abnormalities such as changes in the thalamus, basal ganglia, 
midbrain, pons, and medulla (96,97). Thalamic lesions are the 
most commonly described abnormality; although these can be 
highly specific for JE in the appropriate clinical context, they 
are not a very sensitive marker of JE (98).
Laboratory Diagnosis
JEV infections are confirmed most frequently by detection 
of virus-specific antibody in CSF or serum (12,99–103). 
Because humans have low or undetectable levels of viremia 
by the time distinctive clinical symptoms are recognized, virus 
isolation and nucleic acid amplification tests (NAAT) are 
insensitive and should not be used for ruling out a diagnosis 
of JE (104,105). In one study in Thailand, of 30 nonfatal cases 
involving persons with JEV infection of the central nervous 
system (CNS), none had virus isolated from plasma or CSF 
(100). By contrast, JEV was isolated from CSF in five (33%) 
of 15 fatal cases, and from brain tissue in 8 (73%) of 11 fatal 
cases. More recent studies have shown the utility of NAAT for 
diagnosing JE in some patients with encephalitis or aseptic 
meningitis, but this method still lacks the sensitivity needed 
for routine diagnosis (84,106). 
Acute-phase specimens should be tested for JEV-specific 
immunoglobulin (Ig) M antibodies using a capture enzyme-
linked immunosorbent assay (MAC ELISA) (12,99–103). 
JEV-specific IgM antibodies can be measured in the CSF of 
most patients by 4 days after onset of symptoms and in serum 
by 7 days after onset (99,100). JEV-specific IgM antibodies in 
CSF indicate recent CNS infection and can help distinguish 
clinical disease attributed to JEV from previous vaccination 
(99). With clinical and epidemiologic correlation, a positive 
IgM test has good diagnostic predictive value, but cross-reac-
tion with arboviruses from the same family can occur. Plaque 
reduction neutralization tests (PRNT) can be performed to 
measure virus-specific neutralizing antibodies. A fourfold or 
greater rise in virus-specific neutralizing antibodies between 
acute- and convalescent-phase serum specimens collected 
2–3 weeks apart may be used to confirm recent infection or 
to discriminate between cross-reacting antibodies attributed 
to other primary flaviviral infections. In patients who have 
been infected previously by another flavivirus or vaccinated 
with a flaviviral vaccine (e.g., JE or yellow fever vaccine) and 
who then acquire a secondary flaviviral infection, cross-reactive 
antibodies in both the ELISA and neutralization assays might 
make identifying a specific etiologic agent difficult. Vaccination 
history, date of onset of symptoms, and information regarding 
other arboviruses known to circulate in the geographic area 
that might cross-react in serologic assays should be considered 
when interpreting results. Diagnostic testing for JE is available 
in select state public health laboratories and at CDC’s Division 




JE therapy consists of supportive care and management of 
complications. No specific antiviral agent or other medication 
to mitigate the effects of JEV infection is available (107). In 
controlled clinical trials, corticosteroids, interferon alpha-2a, 
or ribavirin did not improve clinical outcome (108–110).
outcome and Sequelae
JE has a case-fatality ratio of approximately 20%–30% 
(46,47,53,56,62,74,75,82,85–87,111,112). Although some 
motor deficits and movement disorders improve after the acute 
illness, 30%–50% of JE survivors have neurologic or psychiat-
ric sequelae even years later (66,74,82,85,87,93,109,111,113–
117).  These include seizures, upper and lower motor neuron 
weakness, cerebellar and extrapyramidal signs, flexion deformi-
ties of the arms, hyperextension of the legs, cognitive deficits, 
language impairment, learning difficulties, and behavioral 
problems (82). Because of the lack of specific antiviral therapy, 
high case fatality, and substantial morbidity, prevention of JE 
through vaccination and mosquito precautions is important.
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JE Among travelers
For most travelers to Asia, the risk for JE is very low but var-
ies on the basis of destination, duration, season, and activities 
(3,9,10,13,118). The overall incidence of JE among persons 
from nonendemic countries traveling to Asia is estimated to be 
less than one case per 1 million travelers. However, the risk for 
JE among expatriates and travelers who stay for prolonged peri-
ods in rural areas with active JEV transmission is likely similar 
to that among the susceptible resident population. Recurrent 
travelers or travelers on brief trips might be at increased risk 
if they have extensive outdoor or nighttime exposure in rural 
areas during periods of active transmission (119–121). Short-
term (<1 month) travelers whose visits are restricted to major 
urban areas are at minimal risk for JE. Because JEV is main-
tained in an enzootic cycle between animals and mosquitoes, in 
endemic areas where few human cases occur among residents 
as a result of vaccination or natural immunity, susceptible 
visitors might be at risk for infection. JE should be suspected 
in any patient with evidence of a neurologic infection (e.g., 
encephalitis, meningitis, or acute flaccid paralysis) who has 
recently returned from a country in Asia or the western Pacific 
in which JE is endemic.
During 1973–2008, a total of 55 cases of travel-associated JE 
among persons from nonendemic countries were reported in 
the literature (6–8,119–139). A small increase in the number 
of reported cases occurred in each of the three most recent 
10-year periods: 1999–2008 (n = 20), 1989–1998 (n = 17), 
and 1979–1988 (n = 14). Two cases were reported during 
1973–1978, and for two additional published cases, the date 
of onset was unknown but occurred before 1993. Overall, 33 
(60%) cases occurred in tourists, nine (16%) were in expatri-
ates, and six (11%) were in soldiers; the type of travel was 
unknown in seven (13%) cases. The tourist category included 
three case-patients who were traveling to visit friends and rela-
tives and two students on study-abroad programs. The case-
patients were citizens of 17 different countries. The countries 
where infection was most commonly acquired were Thailand 
(n = 19), Indonesia (n = 8), China (n = 7), the Philippines (n 
= 5), Japan (n = 4), and Vietnam (n = 3). Among the 46 cases 
for which age was recorded, patients ranged in age from 1 to 
91 years (median: 34 years); five (9%) of the 55 cases occurred 
among children aged ≤10 years and 10 (18%) among adults 
aged ≥60 years. Overall, 29 (53%) of the 55 case-patients 
were male, and 22 (40%) were female; sex was unknown for 
four cases (7%). Ten (18%) of the reported cases were fatal, 
24 (44%) patients survived but had sequelae, and 12 (22%) 
patients recovered fully; outcome was unknown for nine (16%) 
patients. None of the patients was known to have received JE 
vaccine.
For 37 (67%) of the travel-associated cases, more complete 
information on itineraries and activities was available (8). Many 
reports documented exposures that likely increased risk for 
infection, including travel to rural areas, living in proximity to 
farms or in the jungle, staying in unscreened accommodations, 
or participating in outdoor activities such as trekking. Duration 
of travel for these cases ranged from 10 days to 34 years and was 
≥1 month for 24 (65%) travelers. Of the 13 travelers staying 
<1 month, 10 (77%) had trip duration of 2–<4 weeks, and 
three (23%) traveled for 10–12 days. Among these shorter-term 
travelers, three (23%) travelers spent the majority of their time 
in rural areas, six (46%) stayed in coastal or nonrural areas but 
took day trips to rural areas or national parks, and one (8%) 
stayed in a coastal area and took day trips to unspecified des-
tinations; no exposure-related information was provided for 
three (23%) travelers. No cases occurred among business or 
other short-term travelers who visited only urban areas.
Before 1973, >300 cases of JE were reported among U.S. 
military personnel or their family members (72,79,140–143). 
Of 15 JE cases reported among travelers from the United States 
during 1973–2008, only four were reported after 1992, when 
JE-MB was first licensed in the United States; none of these 
patients had received JE vaccine (7,122).
In 2004, an estimated 5.5 million entries of U.S. travelers 
occurred into JE-endemic countries (144). The proportion of 
these travelers who received JE vaccine or for whom JE vac-
cine should have been recommended is unknown. However, 
<30,000 doses of JE vaccine are distributed annually in the 
U.S. civilian market. A recent survey of adult travelers on direct 
flights from the United States to Asia determined that 415 
(25%) of 1,691 participants described itineraries for which 
JE vaccination should have been considered according to 
ACIP recommendations, including 330 (20%) who planned 
to spend >30 days in a JE-endemic country and another 85 
(5%) shorter-term travelers who planned to spend a substan-
tial proportion of their time in endemic rural areas (145). Of 
these at-risk travelers, only 47 (11%) reported receiving ≥1 
dose of JE vaccine. Among 164 unvaccinated at-risk travelers 
who had visited a health-care provider to prepare for their trip, 
113 (69%) indicated that their health-care provider had not 
offered or recommended JE vaccine. In Europe, an assessment 
based on the number of JE vaccine doses distributed suggested 
that <1% of travelers to endemic countries received JE vac-
cine (118), underscoring the need for health-care providers 
to understand the risks for JE disease among travelers and the 
measures available to prevent it.
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JE Vaccines
JE Vaccines Licensed in the 
United States
Two JE vaccines are licensed in the United States; an inac-
tivated mouse brain–derived vaccine (JE-VAX [JE-MB]) and 
an inactivated Vero cell culture-derived vaccine (IXIARO [JE-
VC]) (Table 1). JE-MB has been licensed in the United States 
since 1992 for use in travelers aged ≥1 year (13,146). In 2006, 
production of JE-MB was discontinued, and the remaining 
supplies are limited. JE-MB had been manufactured in Japan 
by The Research Foundation for Microbial Diseases of Osaka 
University (Biken, Osaka, Japan) and is currently distributed in 
the United States by Sanofi Pasteur (Swiftwater, Pennsylvania). 
In March 2009, FDA approved JE-VC for use in persons aged 
≥17 years (14). JE-VC is manufactured by Intercell Biomedical 
(Livingston, United Kingdom) and is distributed in the United 
States by Novartis Vaccines (Cambridge, Massachusetts). 
Because JE-VC is approved only for use in persons aged 
≥17 years, JE-MB remains the only JE vaccine approved for 
use in children in the United States. To meet the JE vaccine 
needs for children in the United States, Sanofi Pasteur has 
reserved its remaining JE-MB inventory for use in children 
aged 1–16 years. Health-care providers should contact Sanofi 
Pasteur to order doses of JE-MB. Other JE vaccines, including 
live-attenuated SA14-14-2 JE vaccine, are manufactured and 
used in Asia but are not licensed for use in the United States 
(5,147,148). 
Correlates of Protection
Because several effective JE vaccines are available in Asia, 
randomized, controlled efficacy trials to evaluate new JE vac-
cines would be logistically difficult and potentially unethi-
cal. JE-VC was licensed on the basis of its ability to induce 
JEV-specific neutralizing antibodies, which is thought to be 
a reliable surrogate of efficacy (149,150). Observations from 
the 1930s indicated that laboratory workers who had been 
exposed accidentally to JEV were protected from disease 
when they had measurable neutralizing antibodies (151). 
These observations are further supported by passive antibody 
transfer and active immunization studies in animals using both 
licensed and experimental JE vaccines. Subsequent studies in 
mice indicated that passive transfer of neutralizing antibod-
ies protected animals against JEV challenge and established a 
dose-response relationship between antibody titer and level 
of protection (69,151–153). These studies also indicated that 
animals that have been actively primed to respond to JEV 
antigen but that have no detectable neutralizing antibodies 
are protected from lethal challenge, demonstrating an effec-
tive anamnestic immune response (153). A more recent study 
indicated that hyperimmune ascitic fluid raised against two JE 
vaccines derived from genotype III JEV strains (i.e., JE-MB 
derived from the Nakyama-NIH strain and a developmental 
chimeric vaccine derived from the SA14-14-2 strain) protected 
mice against intracerebral challenge with JEV strains of all four 
genotypes. These data demonstrate that neutralizing antibod-
ies provide protection against heterologous JEV genotypes 
(154). In another study, mice were passively immunized with 
pooled sera with JEV neutralizing antibody titers (range: 
20–200 titers) from humans immunized with JE-VC. The mice 
were challenged 18 hours later with a lethal dose of either a 
genotype I (KE093) or genotype III (SA14) JEV strain (155). 
Mice with ex vivo JE neutralizing antibody titers of ≥10 had 
survival rates of 86% (6/7) and 100% (10/10) after challenge 
with the genotype I and III JEV strains, respectively. In mice 
receiving lower-titer sera, protection against JEV challenge 
correlated with the anti-JEV neutralizing antibody titer of the 
immunizing sera. Mice actively vaccinated with varying doses 
of JE-VC and JE-MB also had dose-dependent protection 
against intraperitoneal challenge with the JEV SA14 strain 
(155). Finally, in a study designed to develop a JE animal model 
in nonhuman primates, 16 rhesus macaques were challenged 
intranasally with a 90% effective dose of JEV (i.e., a dose that 
when administered via intranasal challenge would be expected 
to cause encephalitis in 90% of the animals), including four 
monkeys that were immunized with 4 doses of inactivated 
mouse brain–derived JE vaccine, eight monkeys immunized 
with one of two developmental JE poxvirus vaccines, and four 
JEV-naïve control monkeys (156,157). The minimum neutral-
izing antibody titer required to protect the monkeys from lethal 
challenge was between 30 and 46. The higher titers required 
TABLE 1. Composition, storage, dose, and administration of 
inactivated Vero cell culture-derived Japanese encephalitis 
vaccine (JE-VC) and inactivated mouse brain–derived JE 
vaccine (JE-MB)
Characterisitic JE-VC JE-MB
Trade name IXIARO JE-VAX
JEV* strain SA14-14-2 Nakayama-NIH
JEV seed Attenuated Wild-type
Substrate Vero cells Mouse brains
Adjuvant Aluminum hydroxide None
Stabilizer None Porcine gelatin
Preservative None Thimerosal
Final preparation Liquid Lyophilized
Storage 35°– 46°F (2°–8°C) 35°–46°F (2°–8°C)
Dose 0.5 mL 1.0 mL†
Route Intramuscular Subcutaneous
Primary series 2 doses at 0 and 
28 days
3 doses at 0, 7, and 
30 days
Age group ≥17 yrs ≥1 yr
* JE virus.
† 0.5 mL for children aged 1 and 2 years.
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for protection in this study might have been caused by the 
high challenge dose used to develop the model. 
The PRNT is the most commonly accepted test to measure 
functional antibody able to inactivate or neutralize virus. A 
World Health Organization (WHO) expert panel accepted a 
50% PRNT (PRNT50) titer of ≥10 as an immunologic cor-
relate of protection from JE in humans (150). The PRNT50 
titer is the reciprocal of the endpoint serum dilution that 
reduces the challenge virus plaque count by 50%. PRNT is a 
functional assay that can be performed using various protocols, 
and the validity and comparability of PRNT results depend 
on detailed components of the selected assay (e.g., endpoint 
neutralization, incubation conditions, cell substrate, and target 
virus) (150,158). JEV PRNTs are performed only at selected 
reference laboratories, but careful attention must be paid to 
the characteristics and validation of a PRNT assay that is used 
to measure and compare JEV neutralizing titers as a surrogate 
for efficacy. 
Inactivated Vero Cell Culture-
Derived JE Vaccine (IXIARo [JE-VC])
Vaccine Composition, Storage, and 
Handling
JE-VC is an inactivated vaccine derived from the attenu-
ated SA14-14-2 JEV strain propagated in Vero cells (Table 1) 
(14,159,160). Each 0.5-mL dose contains approximately 6 
μg of purified, inactivated JEV proteins and 0.1% aluminum 
hydroxide as an adjuvant. The finished product does not 
include gelatin stabilizers, antibiotics, or thimerosal. 
The vaccine should be stored at 35°–46°F (2°–8°C); it should 
not be frozen. The vaccine should be protected from light. 
During storage, the vaccine might appear as a clear liquid 
with a white precipitate. After agitation, it forms a cloudy 
white suspension.
Immunogenicity of JE-VC
noninferiority of Immunogenicity Compared 
with JE-MB 
No efficacy data exist for JE-VC. The vaccine was licensed 
on the basis of its ability to induce JEV neutralizing anti-
bodies as a surrogate for protection and safety evaluations 
in approximately 5,000 adults. The pivotal noninferiority 
immunogenicity study compared 2 doses of JE-VC given on 
days 0 and 28 to 3 doses of JE-MB given on days 0, 7, and 
28 to adults aged ≥18 years in the United States, Austria, and 
Germany (161). In the “per protocol” analysis, 352 (96%) of 
365 JE-VC recipients developed a PRNT50 ≥10 compared with 
347 (94%) of 370 JE-MB recipients at 28 days after the last 
dose (Table 2) (14,161). The proportion of recipients who sero-
converted differ slightly between the package insert and pub-
lished manuscript because of the inclusion of four additional 
JE-VC recipients and six additional JE-MB recipients in the 
per protocol analysis provided in the package insert (14,161). 
Most subjects in each group had a PRNT50 >40 (Figure 3). The 
PRNT50 geometric mean titer (GMT) for JE-VC recipients 
was 244 compared with 102 for JE-MB recipients. However, 
the target JEV strain in the neutralizing antibody assay was 
SA14-14-2, which is the JEV strain used in JE-VC, whereas 
JE-MB is produced from the Nakayama JEV strain. In a subset 
of these specimens that were evaluated using Nakayama as the 
target JEV strain, the PRNT50 GMT for JE-VC recipients (n 
= 88) was 240 compared with 1,219 for the JE-MB recipients 
(n = 89) (Intercell Biomedical, unpublished data, 2007). In 
another smaller subset of specimens, PRNT50 GMTs against 
other JEV strains were variable (Figure 4) (Intercell Biomedical, 
unpublished data, 2007).
Immunogenicity Data Supporting the 2-Dose 
Primary Series
The licensed vaccine schedule was derived in part on the 
basis of a study that compared two 6-μg doses of vaccine 
administered 28 days apart to a single dose of either 6 μg or 
12 μg (162). At 28 days after receiving 1 dose of the standard 
6-μg regimen, only 95 (41%) of 230 JE-VC recipients had 
seroconverted with a PRNT50 ≥10 (Figure 5). At 56 days 
after receiving their first dose of vaccine, 97% (110/113) of 
the subjects who had received 2 doses had a PRNT50 ≥10 
compared with only 26% (30/117) and 41% (47/114) of the 
subjects who received a single 6-μg or 12-μg dose, respectively. 
All of the 2-dose recipients who seroconverted had protective 
antibodies as early as 7 days after receiving the second dose 
of vaccine.
Immunogenicity in Persons with Preexisting 
Flavivirus Antibodies
A study that evaluated the effect of pre-existing antibodies 
against tick-borne encephalitis virus (TBEV), another flavivi-
rus, determined that TBEV antibodies enhanced the response 
to JE-VC after the first dose but had no effect following the 
2-dose primary series (163). Following 1 dose of JE-VC, 62 
(77%) of 81 subjects with preexisting TBEV IgG antibodies 
developed protective antibodies against JEV compared with 
only 166 (49%) of 339 JE-VC recipients with no preexisting 
TBEV antibodies (Table 3). However, after the second dose of 
JE-VC, subjects with and without TBEV antibodies had simi-
larly high rates of seroconversion against JEV at 96% (78/81) 
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TABLE 2. Seroconversion rates and geometric mean titers for inactivated Vero cell culture-derived Japanese encephalitis vaccine 
(JE-VC) and inactivated mouse brain–derived JE vaccine (JE-MB) recipients at 56 days after the first dose*
Measure
JE-VC† (N = 365) JE-MB§ (N = 370)
Rate difference (CI)SCR (%) (95%CI¶) (%) SCR (%) (CI) (%)
Seroconversion rates (SCR)** †† 96 (94–98) 94 (91–96) 2.6  (-0.5–6.0)§§
(N = 361) (N = 364)
GMT ratio (CI)GMT (CI) GMT (CI)
Geometric mean titers (GMT)†† 244 (216–274) 102 (90–115) 2.3  (2.0–2.8)¶¶
SOURCES: Food and Drug Administration. Product approval information [package insert]. Ixiaro (Japanese encephalitis virus vaccine inactivated). Intercell 
Biomedical, Livingston, United Kingdom. Washington, DC: Food and Drug Administration; 2009. Available at http://www.fda.gov/BiologicsBloodVaccines/
Vaccines/ApprovedProducts/ucm179132.htm. Tauber E, Kollaritsch H, Korinek M, et al. Safety and immunogenicity of a Vero-cell-derived, inactivated 
Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 2007;370:1847–53. 
 * Per-protocol analysis; prevaccination plaque reduction neutralization test (PRNT) <10 for all subjects.
 † Two doses administered at days 0 and 28 with 1 placebo dose at day 7.
 § Three doses administered at days 0, 7, and 28.
 ¶ Confidence interval.
 ** Proportion of vaccinees with 50% PRNT50 titer ≥10 at 56 days after the first dose.
 †† PRNT50 assay used SA14-14-2 JEV strain as the challenge virus.
 §§ Noninferiority of JE-VC compared with JE-MB was demonstrated based on the lower bound of the two-sided CI for the seroconversion rate difference 
(JE-VC minus JE-MB) being > -10% at day 56.
 ¶¶ Noninferiority of JE-VC compared with JE-MB was demonstrated based on the lower bound of the two-sided CI for the GMT ratio (JE-VC/JE-MB) being 
>1/1.5 at day 56.
FIGURE 3. Distribution of 50% plaque reduction neutralization test (PRNT50) titers against the Japanese encephalitis virus (JEV) 
SA14-14-2 strain at 56 days after the first dose of inactivated Vero cell culture-derived JE vaccine (JE-VC) or inactivated mouse 
brain–derived JE vaccine (JE-MB)*
SOURCE: Tauber E, Kollaritsch H, Korinek M, et al. Safety and immunogenicity of a Vero cell-derived, inactivated Japanese encephalitis vaccine: a non-
inferiority, phase III, randomised controlled trial. Lancet 2007;370:1847–53.
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and 91% (310/339), respectively. JEV PRNT50 GMTs were 
also similar between the groups after 2 doses of JE-VC (207 
and 187, respectively).
Duration of neutralizing Antibodies
In a study performed in central Europe to evaluate the 
duration of neutralizing antibodies, 95% (172/181) of the 
subjects who received 2 doses of JE-VC maintained protec-
tive neutralizing antibodies (PRNT50 ≥10) at 6 months after 
receiving the first dose, and 83% (151/181) still had protective 
antibodies at 12 months after the first dose (164). However, 
another study that used similar methods but was performed 
in western and northern Europe concluded that only 83% 
(96/116) of adults receiving 2 doses of JE-VC had protective 
antibodies at 6 months after their first vaccination, and the 
seroprotection rate had dropped to 58% (67/116) and 48% 
(56/116) at 12 and 24 months, respectively (165). Among 44 
subjects who no longer had protective antibodies (17 subjects 
at 6 months after their first dose and 27 subjects at 12 months 
after their first dose), all developed PRNT50 ≥10 after receiv-
ing a booster dose.
FIGURE 5. Percentage of inactivated Vero cell culture-derived 
JE vaccine (JE-VC) recipients with 50% plaque reduction neu-
tralization test (PRNT50) titers ≥10, by dosing regimen*
SOURCE: Schuller E, Klade CS, Wolfl G, Kaltenbock A, Dewasthaly S, 
Tauber E. Comparison of a single, high-dose vaccination regimen to the 
standard regimen for the investigational Japanese encephalitis vaccine, 
IC51: a randomized, observer-blind, controlled Phase 3 study. Vaccine 
2009;27:2188–93.
* PRNT50 ≥10 is considered a surrogate of immunity.
† Two doses administered at days 0 and 28.
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FIGURE 4. Comparison of 50% plaque reduction neutralization test (PRNT50) geometric mean titers (GMT) with selected Japanese 
encephalitis virus (JEV) strains at 56 days after the first dose of inactivated Vero cell culture-derived JE vaccine (JE-VC) or inac-
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SOURCE: Intercell Biomedicals, unpublished data, 2007.
* PRNT50 ≥10 is considered a surrogate of immunity.
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Comcomitant Administration of Hepatitis A 
Vaccine
A clinical trial in which the first dose of JE-VC was adminis-
tered concomitantly with hepatitis A vaccine (HAVRIX) indi-
cated no interference with the immune response to JE-VC or 
hepatitis A vaccine (166). Among the 58 subjects who received 
both JE-VC and hepatitis A vaccine in the per-protocol 
analysis, all had protective neutralizing antibodies against the 
SA14-14-2 JEV strain compared with 98% (57/58) of subjects 
who received JE-VC alone (Table 4). PRNT50 GMTs also were 
similar at 203 and 192, respectively. Subjects receiving JE-VC 
and hepatitis A vaccine also had similar seroconversion rates 
for anti-hepatitis A virus (anti-HAV) antibody (100%; 58/58) 
compared with subjects receiving hepatitis A vaccine alone 
(96%; 50/52). However, some differences were noted between 
men and women in the levels of anti-HAV antibody achieved, 
and both seroconversion rates and antibody titers varied 
depending on which anti-HAV assay was used. Whether these 
observations have any clinical significance is not known.
Immunogenicity in Children
A phase 2 trial investigated the safety and immunogenicity 
of JE-VC in healthy children aged 1 and 2 years in India, using 
a standard (6-μg) or half (3-μg) dose (167). Children in both 
groups received 2 doses of JE-VC administered 28 days apart. 
A third group of children received 3 doses of an inactivated 
mouse brain–derived JE vaccine (JenceVac) on days 0, 7, and 
28. JenceVac is produced by the Korean Green Cross Vaccine 
Corporation and is not licensed in the United States. At 28 days 
after the vaccination series was complete, seroconversion rates 
in the 6-μg (n = 21) and 3-μg (n = 23) JE-VC recipient groups 
and the inactivated mouse brain–derived group (n = 11) were 
95%, 96%, and 91%, and PRNT50 GMTs were 218 (95% 
confidence interval [CI] = 121–395), 201 (CI = 106–380), 
and 230 (CI = 68–784), respectively. None of the differences 
in seroconversion rates or GMTs was statistically significant. 
Further pediatric clinical trials are planned.
Adverse Events with JE-VC
Local and systemic adverse events caused by JE-VC are 
similar to those reported for JE-MB or placebo adjuvant alone. 
No serious hypersensitivity reactions or neurologic adverse 
events were identified among JE-VC recipients enrolled in the 
clinical trials. However, because JE-VC was studied in <5,000 
adults, the possibility of rare serious adverse events cannot be 
excluded. Additional postlicensure studies and monitoring of 
surveillance data are planned to evaluate the safety of JE-VC 
in a larger population.
Local and Systemic Adverse Events of JE-VC 
Compared with Placebo Adjuvant
The pivotal safety study comparing 1,993 subjects who 
received 2 doses of JE-VC with 657 subjects who received 2 
doses of placebo adjuvant (phosphate buffered saline with 0.1% 
aluminum hydroxide) indicated similar reactogenicity and 
adverse events (Tables 5 and 6) (168). The most common local 
reactions after JE-VC administration were pain and tender-
ness. Two cases of urticaria were noted during the study: one 
case of urticaria localized to both inner thighs that occurred 
6 days after the second vaccination in the placebo group, and 
one case of generalized urticaria (affecting the face, chest, 
TABLE 3. Number and percentage of inactivated Vero cell 
culture-derived Japanese encephalitis vaccine (JE-VC) 
recipients with 50% plaque reduction neutralization test 








p-valueNo. (%) No. (%)
After 1 dose 
(day 28)†
62 (77) 166 (49) <0.01
After 2 doses 
(day 56)†
78 (96) 310 (91) 0.17
SOURCE: Schuller E, Klade CS, Heinz FX, et al. Effect of pre-existing anti-
tick-borne encephalitis virus immunity on neutralising antibody response 
to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine 
candidate IC51. Vaccine 2008;26:6151–6.
* Based on TBEV IgG enzyme-linked immunosorbent assay.
† Two doses of JE-VC were administered at days 0 and 28.
TABLE 4. Immunogenicity of inactivated Vero cell culture-
derived Japanese encephalitis vaccine (JE-VC) and hepatitis 











JEV¶ PRNT50** ≥10†† 100% 98% — §§
JEV PRNT50 GMT¶¶ 203 192 —
HAV*** seroconversion††† 100% — 96%
HAV antibody GMT††† 150 — 124
SOURCE: Kaltenbock A, Dubischar-Kastner K, Eder G, et al. Safety and 
immunogenicity of concomitant vaccination with the cell-culture based 
Japanese encephalitis vaccine IC51 and the hepatitis vaccine HAVRIX1440 
in healthy subjects–a single-blind, randomized, controlled phase 3 study. 
Vaccine 2009;27:4483–9.
 * Two doses of JE-VC administered at days 0 and 28 and 1 dose of 
hepatitis A vaccine administered at day 0.
 † Two doses of JE-VC administered at days 0 and 28 and 1 dose of 
placebo at day 0.
 § One dose of hepatitis A vaccine at day 0 and 2 doses of placebo at 
days 0 and 28.
 ¶ JE virus.
 ** Plaque reduction neutralization test with a cutoff value of 50%.
 †† Measured at 56 days after the first dose.
 §§ Not reported.
 ¶¶ Geometric mean titer.
*** Hepatitis A virus.
 ††† Measured at 28 days after the dose of hepatitis A vaccine.
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arms, and abdomen) that occurred 8 days after the second 
vaccination in the JE-VC group. The case of urticaria in the 
JE-VC group was described as being of “moderate intensity”; 
it was treated with cetirizine hydrochloride and resolved after 
3 days. Angioedema was not observed. The event was consid-
ered by the investigator to be unlikely to be related to study 
vaccine, and the subject completed the study. A total of 17 
subjects, 12 (0.6%) in the JE-VC group and five (0.8%) in 
the placebo group, terminated the study prematurely because 
of adverse events. Two of the events (gastroenteritis and rash) 
in the JE-VC group were severe, and eight of them (headache 
[two events], influenza-like illness, allergic dermatitis, injec-
tion site pain, nausea, fatigue, and rash [one event each]) were 
considered to be at least possibly related to study treatment. 
No serious neurologic events were identified.
Local and Systemic Adverse Events of JE-VC 
Compared with JE-MB
In the noninferiority immunogenicity trial, the frequency 
of adverse events reported following JE-VC vaccination (428 
subjects) was similar to that reported by persons receiving 
JE-MB (435 subjects) (161). Severe redness, swelling, ten-
derness, and pain at the injection site were each reported by 
≤1% of JE-VC recipients (Table 7). Reported systemic adverse 
events following JE-VC vaccination generally were mild; the 
most commonly reported adverse events in the 7 days after 
each dose were headache (26%), myalgia (21%), influenza-like 
illness (13%), and fatigue (13%). One serious adverse event 
was reported in the JE-VC group; a male aged 50 years had a 
nonfatal myocardial infarction 3 weeks after the second vac-
cination. The event was considered by the investigator to be 
unlikely to be related to study vaccine.
Pooled Safety Data
In a pooled analysis of 6-month safety data from seven stud-
ies, severe injection-site reactions were reported by 3% of the 
3,558 JE-VC subjects, which was comparable to the 3% among 
657 placebo adjuvant recipients but lower than the 14% among 
435 JE-MB recipients (169). Systemic symptoms were reported 
with similar frequency among subjects who received JE-VC 
(40%), JE-MB (36%), or placebo (40%). Serious adverse 
events were reported by 1% of the subjects in the JE-VC group. 
Serious allergic reactions were not observed in any study group, 
including JE-VC, JE-MB, or placebo recipients.
Vaccination of Women During 
Pregnancy and Breastfeeding
FDA classifies JE-VC as a “Pregnancy Category B” medi-
cation (14). No controlled studies have assessed the safety, 
immunogenicity, or efficacy of JE-VC in pregnant women. 
Preclinical studies of JE-VC in pregnant rats did not show 
evidence of harm to the mother or fetus. No data exist on the 
safety or efficacy of JE-VC in breastfeeding women. 
TABLE 6. Percentage of local reactions within 7 days after each dose of inactivated Vero cell culture-derived Japanese encephalitis 
vaccine (JE-VC) or placebo adjuvant (PBS + 0.1% aluminum hydroxide)*














Pain 28 28 18 18 33 36
Tenderness 29 27 23 18 36 33
Erythema 7 5 5 4 10 7
Induration 5 5 4 3 8 7
Edema 2 3 2 2 4 5
Pruritis 3 3 2 2 4 5
SOURCES: Food and Drug Administration. Product approval information [package insert]. Ixiaro (Japanese encephalitis virus vaccine inactivated). Intercell 
Biomedical, Livingston, United Kingdom. Washington, DC: Food and Drug Administration; 2009. Available at http://www.fda.gov/BiologicsBloodVaccines/
Vaccines/ApprovedProducts/ucm179132.htm. Tauber E, Kollaritsch H, von Sonnenburg F, et al. Randomized, double-blind, placebo-controlled phase 3 trial 
of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis 2008;198:493–9.
* Two doses administered at days 0 and 28.
TABLE 5. Number and percentage of adverse events occurring 
within 56 days after the first dose of inactivated Vero cell 
culture-derived Japanese encephalitis vaccine (JE-VC) or 





Placebo adjuvant  
(N = 657)
No. (%) No. (%)
Any 1,173 (59) 372 (57)
Medically attended 254 (13) 80 (12)
Serious 10 (0.5) 6 (0.9)
Terminated study 12 (0.6) 5 (0.8)
SOURCE: Tauber E, Kollaritsch H, von Sonnenburg F, et al. Randomized, 
double-blind, placebo-controlled phase 3 trial of the safety and toler-
ability of ic51, an inactivated Japanese encephalitis vaccine. J Infect Dis 
2008;198:493–9.
* Two doses administered at days 0 and 28.
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Inactivated Mouse Brain–Derived 
JE Vaccine (JE-VAX [JE-MB])
Vaccine Composition, Storage, and 
Handling
JE-MB is an inactivated vaccine prepared by inoculating 
mice intracerebrally with the JEV Nakayama-NIH strain 
(Table 1) (146). Thimerosal is added as a preservative to a final 
concentration of 0.007%. Each 1.0-mL dose also contains 
approximately 500 μg of gelatin, <100 μg of formaldehyde, 
<0.0007% v/v Polysorbate 80, and <50 ng of mouse serum 
protein. No myelin basic protein can be detected at the detec-
tion threshold of the assay (<2 ng/mL).
The lyophilized vaccine should be stored at 35°–46°F 
(2°–8°C); it should not be frozen. The vaccine should be recon-
stituted according to the package insert only with the supplied 
diluent. After reconstitution the vaccine should be stored at 
35°–46°F (2°–8°C) and used within 8 hours. Reconstituted 
vaccine should not be frozen.
Efficacy of Inactivated Mouse Brain–
Derived JE Vaccine
An inactivated mouse brain–derived JE vaccine was first 
licensed in Japan in 1954 and then modified in the 1960s and 
1980s. Similar vaccines are produced in several Asian countries 
using the Nakayama or Beijing-1 JEV strains. Inactivated 
mouse brain–derived vaccines have been used effectively to 
control disease in several JE-endemic countries, including 
Japan, South Korea, Taiwan, and Thailand. They also have 
been used for several decades to prevent infection in tourists 
and military personnel from nonendemic countries traveling 
to JE-endemic regions.
Efficacy of inactivated mouse brain–derived JE vaccine has 
been demonstrated in two large controlled trials. A precursor 
of the current mouse brain–derived JE vaccine was studied in 
Taiwan in 1965 (170). Approximately 265,000 children were 
enrolled and received 1 dose of JE vaccine (22,194 children), 
2 doses of JE vaccine (111,749 children), or tetanus toxoid 
(131,865 children). Another 140,514 unvaccinated children 
also were observed. After 1 year of follow-up, JE incidence 
among children who received 2 doses of JE vaccine was 3.6 
per 100,000 population compared with 18.2 per 100,000 in 
recipients of tetanus toxoid, for a vaccine efficacy of approxi-
mately 80%. A single dose of JE vaccine was not efficacious.
Efficacy of JE-MB was demonstrated in a placebo-controlled, 
randomized trial conducted among 65,000 children aged 1–14 
years in Thailand (68). Study participants were randomized 
to receive 2 doses of monovalent vaccine prepared with the 
Nakayama-NIH JEV strain administered 7 days apart (21,628 
children), 2 doses of a bivalent JE vaccine that contained 
both the Nakayama-NIH and Beijing-1 JEV strains (22,080 
children), or tetanus toxoid (21,516 children). After 2 years, 
one JE case was identified in each of the two study vaccine 
groups (five cases per 100,000) compared with 11 JE cases 
(51 cases per 100,000) in the children who received tetanus 
toxoid. The efficacy in both JE vaccine groups combined was 
91% (CI = 70%–97%) with no difference observed between 
the monovalent and bivalent vaccines.
Immunogenicity of Inactivated Mouse 
Brain–Derived JE Vaccine
Immunogenicity of 2 Versus 3 Doses for 
travelers
For travelers from nonendemic countries, the recommended 
primary vaccination series for JE-MB is 3 doses administered 
on days 0, 7, and 30. Children in JE-endemic countries usually 
receive 2 doses of inactivated mouse brain–derived JE vaccine 
separated by 1–4 weeks and followed by a booster dose 1 year 
later (147). However, immunogenicity studies performed in 
adults from nonendemic countries indicated that ≤80% of par-
ticipants seroconverted following 2 doses of vaccine and only 
about 30% still had measurable neutralizing titers after 6–12 
TABLE 7. Number and percentage of local and systemic 
adverse events occurring within 7 days after administration 
at days 0 and 28 of inactivated Vero cell culture-derived 
Japanese encephalitis vaccine (JE-VC) or inactivated mouse 
brain–derived JE vaccine (JE-MB)*
Severe local  
  adverse events
JE-VC† JE-MB§
No. (%) No. (%)
(n = 421) (n = 427)
Redness 4 (1) 46 (11)
Swelling 3 (1) 23 (5)
Hardness 4 (1) 25 (5)
Any¶ 9 (2) 59 (14)
Systemic  
  adverse events (n = 428) (n = 435)
Headache 113 (26) 125 (29)
Myalgia 88 (21) 69 (16)
Influenza-like illness 54 (13) 55 (13)
Fatigue 54 (13) 48 (11)
SOURCE: Tauber E, Kollaritsch H, Korinek M, et al. Safety and immu-
nogenicity of a Vero-cell-derived, inactivated Japanese encephalitis 
vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 
2007;370:1847–53.
* Analysis includes all participants who entered into the study and received 
≥1 dose of vaccine
† Two doses administered at days 0 and 28 with one dose placebo at 7 
days.
§ Three doses administered at days 0, 7, and 28.
¶ Difference between two vaccines p<0.01 (Fisher’s exact test).
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months. By contrast, between 87% and 100% of adults from 
nonendemic settings developed neutralizing antibodies after 
receiving 3 doses of vaccine (Table 8) (13,138,171–173). The 
vaccine’s efficacy and immunogenicity after 2 doses in Asian 
subjects might be a result of prior immunity or subsequent 
exposures to flaviviruses present in Asia including JEV, West 
Nile virus, and dengue virus (174). Although exposure to fla-
viviruses is almost universal at an early age in most countries 
in Asia, flaviviral infections are much less common in North 
America and Europe.
Immunogenicity of two 3-Dose Regimens
The immunogenicity of two different, 3-dose vaccination 
regimens was evaluated in 528 U.S. military personnel in 1990 
(173). Vaccine was given on days 0, 7, and either 14 or 30. 
All vaccine recipients demonstrated neutralizing antibodies at 
2 months and 6 months after initiation of vaccination. The 
longer schedule of days 0, 7, and 30 produced higher antibody 
titers than the days 0, 7, and 14 schedule. When 273 of the 
original study participants were tested at 12 months after vac-
cination, a statistically significant difference in GMTs did not 
exist between the two groups (146).
neutralizing Antibodies Following a 
Booster Dose
Marked anamnestic responses with ≥10-fold increases in 
neutralizing antibody titers have been demonstrated after a 
booster dose of JE-MB (147,175,176). In a study in Japan, 
among 152 subjects who had received either a 1- or 2-dose 
primary vaccination schedule, a booster dose at 1 year increased 
neutralizing antibody GMTs from ≤20 immediately prior to 
the booster to ≥1,360 at 4 weeks (175).
Duration of neutralizing Antibodies
Only a few studies have measured the duration of protection 
after primary or booster vaccinations in populations from non-
endemic or low-endemicity areas. Studies conducted in most 
parts of Asia are complicated by the boosting effect of naturally 
acquired flaviviral infections. In U.S. military personnel who 
received a 3-dose primary vaccination course, 100% (21/21) 
and 94% (16/17) still had protective neutralizing antibody 
titers at 2 years and 3 years, respectively (177). In a study in 
a nonendemic area of Japan, 38 (92%) of 41 recipients main-
tained protective antibody titers 2 years after a booster dose 
(175). Another study in an area of low JE endemicity in Japan 
applied a random coefficient model to data from 17 children 
and estimated that 82% would have protective antibodies at 5 
years after a booster dose (4th dose) of vaccine and that 53% 
would still be protected 10 years following the booster dose 
(178). In contrast to these studies, which indicated persistence 
of immunity for several years, a study conducted on Badu 
Island in the Torres Strait, Australia, indicated that only 70 
(32%) of 219 persons had protective antibodies 30–36 months 
after either primary vaccination or receipt of a booster dose 
(179). The reason for the unusually low level of immunity in 
this study was not clear, although high prevalence of chronic 
medical conditions among the population studied was pro-
posed as a contributing factor.
Immunogenicity in Persons with Preexisting 
Flavivirus Antibodies
Immunogenicity studies with another flaviviral vaccine 
(inactivated tick-borne encephalitis [TBE] vaccine) have indi-
cated that previous yellow fever vaccination augmented the 
antibody response to TBE vaccine (180). This effect has not 
been observed among JE-MB recipients (135,173).
Adverse Events with Inactivated 
Mouse Brain–Derived JE Vaccine
Local and Systemic Adverse Events
Inactivated mouse brain–derived JE vaccine has been associ-
ated with localized erythema, tenderness, and swelling at the 
injection site in about 20% of recipients. Mild systemic side 
effects (e.g., fever, chills, headache, rash, myalgia, and gastroin-
TABLE 8. Seroconversion with inactivated mouse brain–derived 
Japanese encephalitis vaccine in previously unvaccinated 
persons from countries where disease is not endemic
Study





A* 5 / 14 (36) 41 / 47 (87)
B† 91 / 118 (77) 71 / 72 (99)
C§ 16 / 20 (80) 25 / 25 (100)
D¶ —** — 470 / 470 (100)
 * SOURCE: Henderson A. Immunisation against Japanese encephalitis in 
Nepal: experience of 1152 subjects. J R Army Med Corps 1984;130:188–
91.Two doses administered at 0 and 10 days, or three doses at 0, 10, 
and 20 days. Serum collected at 10 days after last dose.  Study includes 
British army soldiers stationed in Nepal, Nepalese soldiers, and civilian 
employees.
 † SOURCE: Poland JD, Cropp CB, Craven RB, Monath TP. Evaluation of 
the potency and safety of inactivated Japanese encephalitis vaccine in 
US inhabitants. J Infect Dis 1990;161:878–82.Two doses administered 
at 0 and 1–2 weeks, or three doses at 0, 1–2, and 4 weeks. Serum col-
lected 1 month after last dose. 
 § SOURCE: Sanchez JL, Hoke CH, McCown J, et al. Further experience 
with Japanese encephalitis vaccine. Lancet 1990;335:972–3. Two doses 
administered at 0 and 1 week, or three doses at 0, 1, and 26 weeks. 
Serum collected at 8 weeks or 30 weeks.
 ¶ SOURCE: Defraites RF, Gambel JM, Hoke CH, Jr., et al. Japanese en-
cephalitis vaccine (inactivated, BIKEN) in U.S. soldiers: immunogenicity 
and safety of vaccine administered in two dosing regimens. Am J Trop 
Med Hyg 1999;61:288–93. Three doses administered at 0, 7, and either 
14 or 30 days. Serum collected at 2 months.
 ** Not reported.
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testinal symptoms) have been reported in approximately 10% 
of vaccinees (138,146,173). 
Allergic Hypersensitivity Reactions
JE-MB has been associated with serious, but rare, allergic 
and neurologic adverse events. Allergic hypersensitivity reac-
tions, including generalized urticaria and angioedema of the 
extremities, face, and oropharynx, have been reported primarily 
among adult travelers and military personnel (13,66,147,181–
188). Accompanying bronchospasm, respiratory distress, and 
hypotension were observed in some patients. Although most of 
these reactions occurred within 24–48 hours after the first dose, 
when they occurred following a subsequent dose, symptom 
onset often was delayed (median: 3 days; range: 1–14 days) 
(185). Most of these reactions were treated with antihistamines 
or corticosteroids on an outpatient basis; however, up to 
10% of vaccinees with these reactions have been hospitalized. 
Several deaths attributed to anaphylactic shock have been 
associated temporally with receipt of this vaccine, but none 
of these patients had evidence of urticaria or angioedema, and 
two had received other vaccines simultaneously (43,185,189). 
Estimates of the frequency of severe hypersensitivity reactions 
range from 10 to 260 cases per 100,000 vaccinees, and vary 
by country, year, case definition, surveillance method, and 
vaccine lot (Table 9) (13,181–188). Persons with a history of 
anaphylaxis, urticaria, or other allergies are 2–11 times more 
likely to develop a hypersensitivity reaction following receipt 
of JE vaccine (185,190). Gelatin, which is used as a vaccine 
stabilizer, might be responsible for some of these allergic reac-
tions (191–193). In one study from Japan, among 10 children 
who developed an immediate hypersensitivity reaction within 
1 hour after receiving inactivated mouse brain–derived JE vac-
cine, all had measurable IgE antibodies against gelatin (193). 
By contrast, only one (4%) of 28 children who developed 
a delayed hypersensitivity reaction at 1–48 hours following 
administration of inactivated mouse brain–derived JE vac-
cine, and none of 15 controls had evidence of anti-gelatin 
IgE antibodies.
neurologic Adverse Events
JE-MB contains no myelin basic protein at the detection 
threshold of the assay. However, the use of mouse brains as the 
substrate for virus growth has raised concerns about the pos-
sibility of neurologic side effects associated with the JE vaccine. 
Moderate to severe neurologic symptoms, including encepha-
litis, seizures, gait disturbances, and parkinsonism, have been 
reported at a rate of 0.1–2 cases per 100,000 vaccinees with 
variation by country, case definition, and surveillance method 
(Table 9) (13,186,188,194). In addition, cases of severe or fatal 
acute disseminated encephalomyelitis (ADEM) temporally 
associated with JE vaccination of children in Japan and Korea 
have been reported (43,186,195–199). In 2005, in response to 
these cases, Japan suspended routine vaccination with mouse 
brain–derived JE vaccines (5,200). In reviewing this decision, 
the WHO Global Advisory Committee on Vaccine Safety 
determined that no evidence existed of an increased risk for 
ADEM associated with mouse brain–derived JE vaccine and 
that a causal link had not been demonstrated. The committee 
recommended that, although current use and policies should 
not be changed, the inactivated mouse brain–derived vaccine 
should be replaced gradually by new-generation JE vaccines 
(5,200).
Vaccination of Women During 
Pregnancy and Breastfeeding
FDA classifies JE-MB as a “Pregnancy Category C” medica-
tion (146). No specific information is available on the safety 
of JE-MB in pregnant women, and animal reproductive stud-
ies have not been conducted with JE-MB. In addition, no 
data exist on the safety or efficacy of JE-MB in breastfeeding 
women. 
TABLE 9. Incidence of allergic hypersensitivity reactions 
and neurologic events temporally associated with receipt 
of inactivated mouse brain–derived Japanese encephalitis 
vaccines 
Event Cases Denominator Incidence*
Allergic hypersensitivity reactions
Japan (NARRS†) 71 9,400,000 doses 1
United States (VAERS§) 51 813,822 doses 6
Sweden 1 15,000 vaccinees 10
United Kingdom 1 1,950 vaccinees 50
Denmark 21 41,500 vaccinees 50
Australia 7 4,000 vaccinees 200
United States 38 14,249 vaccinees 266
Neurologic events
Japan (1965–1973) NR¶ Vaccinees 0.1
Japan (1996–1998) 17 9,400,000 doses 0.2
United States (1993–1998) 2 813,822 doses 0.2
Denmark (1983–1996) 10 384,000 doses 2.6
SOURCES: Berg SW, Mitchell BS, Hanson RK, et al. Systemic reactions 
in U.S. Marine Corps personnel who received Japanese encephalitis vac-
cine. Clin Infect Dis 1997;24:265–6. Takahashi H, Pool V, Tsai TF, Chen 
RT. Adverse events after Japanese encephalitis vaccination: review of 
post-marketing surveillance data from Japan and the United States. The 
VAERS Working Group. Vaccine 2000;18:2963–9. Plesner AM. Allergic 
reactions to Japanese encephalitis vaccine. Immunol Allergy Clin North 
Am 2003;23:665–97. Plesner AM, Arlien-Soborg P, Herning M. Neurological 
complications to vaccination against Japanese encephalitis. Eur J Neurol 
1998;5:479–85.
* Per 100,000 population.
† National Adverse Reaction Reporting System.
§ Vaccine Adverse Event Reporting System.
¶ Not reported.
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Cost Effectiveness of JE Vaccines
Several studies have demonstrated that using JE vaccine 
to immunize children in JE-endemic countries is cost saving 
(201–203). However, given the large numbers of travelers to 
Asia (5.5 million entries of U.S. travelers into JE-endemic 
countries in 2004), the very low risk for JE for most travelers 
to Asia (less than one case per 1 million travelers), and the high 
cost of JE vaccine ($390 per 2-dose primary series for JE-VC 
in 2009) (204), providing JE vaccine to all travelers to Asia 
would not be cost-effective. In addition, for some travelers, 
even a low risk for serious adverse events attributable to JE 
vaccine might be higher than the risk for disease. Therefore, 
JE vaccine should be targeted to travelers who, on the basis 
of their planned travel itinerary and activities, are at increased 
risk for disease. Travel vaccines typically are not covered by 
insurance plans, and the travelers themselves usually must 
pay for vaccine administration. Therefore, travelers should 
be counseled about their individual risk on the basis of their 
planned itinerary and activities.
Summary of Rationale for JE 
Vaccine Recommendations
When making recommendations regarding the use of JE vac-
cine for travelers, health-care providers should weigh the overall 
low risk for travel-associated JEV disease, the high morbidity 
and mortality when JE does occur, the low probability of seri-
ous adverse events following vaccination, and the cost of the 
vaccine. Evaluation of an individual traveler’s risk should take 
into account their planned itinerary including travel location, 
duration, season, and activities (Box 1).
The risk for JE for most travelers to Asia is very low but 
varies based on destination, duration, season, and activities 
(3,8–10,13,118). Since 1992, when a vaccine was first licensed 
for use in the United States, only four cases of JE have been 
reported among travelers from the United States; none of the 
patients had received JE vaccine. The overall incidence of JE 
among people from nonendemic countries traveling to Asia 
is estimated to be less than one case per 1 million travelers. 
However, the risk for JE among expatriates and travelers 
who stay for prolonged periods in rural areas with active JEV 
transmission is likely similar to the risk among the susceptible 
resident population (6,9). Recurrent travelers or travelers on 
brief trips might be at increased risk if they have extensive 
outdoor or nighttime exposure in rural areas during periods 
of active transmission (119–121). Short-term (<1 month) 
travelers whose visits are restricted to major urban areas are at 
minimal risk for JE.
BOX 1. Factors to consider when evaluating a traveler’s risk 
for Japanese encephalitis virus (JEV) exposure
Destination
JE occurs in areas throughout most of Asia and parts •	
of the western Pacific.
The highest risk of JEV exposure occurs in rural agri-•	
cultural areas, often associated with rice production 
and flooding irrigation.
JE can occur in large, focal outbreaks indicating •	
extensive active JEV transmission in that area.
Duration of travel
Most reported travel-associated JE cases have •	
occurred among expatriates or long-term travelers 
(i.e., ≥1 month).
Although no specific duration of travel puts a •	
traveler at risk for JE, a longer itinerary increases 
the likelihood that a traveler might be exposed to 
a JEV-infected mosquito.
Season
In most temperate areas of Asia, JEV transmission is •	
seasonal, and human disease usually peaks in sum-
mer and fall.
In the subtropics and tropics, JEV transmission •	
patterns vary, and human disease can be sporadic 
or occur year-round.
Activities
The mosquitoes that transmit JEV feed on humans •	
most often in the outdoors, with peak feeding times 
after sunset and again after midnight. 
Extensive outdoor activities (e.g., camping, hiking, •	
trekking, biking, fishing, hunting, or farming), espe-
cially during the evening or night, increase the risk 
of being exposed to a JEV-infected mosquito.
Accommodations with no air conditioning, screens, •	
or bed nets increase the risk of exposure to mos-
quitoes that transmit JEV and other vector-borne 
diseases (e.g., dengue and malaria).
Additional information
Information on expected JEV transmission by coun-•	
try is available from CDC at http://wwwnc.cdc.
gov/travel/yellowbook/2010/chapter-2/japanese-
encephalitis.aspx.
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The highest risk for JEV exposure occurs in rural agricultural 
areas, often those associated with rice production and flooding 
irrigation. In most temperate areas of Asia, JEV transmission 
is seasonal, and human disease usually peaks in summer and 
fall. In the subtropics and tropics, transmission patterns vary, 
and human disease can be sporadic or occur year-round.
Although no minimum duration of travel eliminates a 
traveler’s risk for JE, a longer itinerary increases the likeli-
hood that a traveler will spend time in an area with active JEV 
transmission. The mosquitoes that transmit JEV feed most 
often in the outdoors with peaks after sunset and again after 
midnight. Outdoor activities, especially during the evening 
or night, increase the risk for being exposed to a JEV-infected 
mosquito.
Recommendations for the 
Prevention of JE Among travelers
Travelers to JE-endemic countries should be advised of the 
risks of JEV disease and the importance of personal protec-
tive measures to reduce the risk for mosquito bites. For some 
travelers who will be in a high-risk setting based on season, 
location, duration, and activities, JE vaccine can further reduce 
the risk for infection. 
Personal Protective Measures
All travelers should take precautions to avoid mosquito bites 
to reduce the risk for JE and other vector-borne infectious dis-
eases (Box 2). These precautions include using insect repellent, 
permethrin-impregnated clothing, and bed nets, and staying 
in accommodations with screened or air-conditioned rooms. 
Additional information on protection against mosquitoes and 
other arthropods is available at http://wwwnc.cdc.gov/travel/
yellowbook/2010/chapter-2/protection-against-mosquitoes-
ticks-insects-arthropods.aspx.
Recommendations for the Use of JE 
Vaccine
JE vaccine is recommended for travelers who plan to spend a 
month or longer in endemic areas during the JEV transmission 
season (Box 3). This includes long-term travelers, recurrent 
travelers, or expatriates who will be based in urban areas but 
are likely to visit endemic rural or agricultural areas during a 
high-risk period of JEV transmission.
JE vaccine should be considered for the following 
persons:
Short-term (<1 month) travelers to endemic areas during •	
the JEV transmission season if they plan to travel out-
side of an urban area and have an increased risk for JEV 
exposure. Examples of higher-risk activities or itineraries 
include 1) spending substantial time outdoors in rural or 
agricultural areas, especially during the evening or night; 2) 
participating in extensive outdoor activities (e.g., camping, 
hiking, trekking, biking, fishing, hunting, or farming); and 
3) staying in accommodations without air conditioning, 
screens, or bed nets.
Travelers to an area with an ongoing JE outbreak.•	
Travelers to endemic areas who are uncertain of specific •	
destinations, activities, or duration of travel.
JE vaccine is not recommended for short-term travelers 
whose visit will be restricted to urban areas or times outside 
of a well-defined JEV transmission season.
Information on expected JEV transmission by country can 
be obtained from CDC at http://wwwnc.cdc.gov/travel/yel-
lowbook/2010/chapter-2/japanese-encephalitis.aspx. These 
data should be interpreted cautiously because JEV transmission 
activity varies within countries and from year to year.
Recommendations for the Use of JE 
Vaccines in Laboratory Workers
At least 22 laboratory-acquired JEV infections have been 
reported in the literature (205). Although work with JEV is 
restricted to Biosafety Level 3 (BSL-3) facilities and practices, 
JEV might be transmitted in a laboratory setting through 
needlesticks, and theoretically, through mucosal or inhalational 
accidental exposures. Vaccine-induced immunity presum-
ably protects against exposure through a percutaneous route. 
Exposure to aerosolized JEV, and particularly to high concen-
BOX 2. Personal protective measures to reduce the risk 
forJapanese encephalitis and other vectorborne infectious 
diseases
All travelers should take precautions to avoid mos-•	
quito bites to reduce the risk of Japanese encephalitis 
and other vectorborne infectious diseases
Use insect repellent –
Wear permethrin-impregnated clothing –
Sleep under permethrin-impregnated bed nets –
Stay in accommodations with air conditioning  –
or screens
Additional information on protection against mos-•	
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trations of virus, that might occur during viral purification, 
potentially could lead to infection through mucous membranes 
and possibly directly into the central nervous system through 
the olfactory epithelium. Whether vaccination provides protec-
tion following such exposures is unknown, but vaccination is 
recommended for all laboratory workers with a potential for 
exposure to infectious JEV (Box 3).
Administration of JE Vaccines
Dosage and Administration
JE-VC
The primary vaccination series for JE-VC is 2 doses admin-
istered 28 days apart (Table 1). Each 0.5-mL dose is given by 
the intramuscular route; this route is different from that of 
JE-MB, which is administered subcutaneously. JE-VC is sup-
plied in 0.5-mL single-dose syringes. The 2-dose series should 
be completed at least 1 week before potential exposure to JEV. 
The dose is the same for all persons aged ≥17 years. The vaccine 
is not licensed for use in persons aged <17 years.
JE-MB
For travelers, the recommended primary vaccination series 
for JE-MB is 3 doses administered subcutaneously on days 
0, 7, and 30 (Table 1). An abbreviated schedule (days 0, 7, 
and 14) can be used when the longer schedule is impractical. 
Both regimens produce similar rates of seroconversion among 
recipients, but neutralizing antibody titers at 2 and 6 months 
are lower following the abbreviated schedule. Among 80% 
of vaccinees, 2 doses, administered 1 week apart, will confer 
short-term immunity. However, this schedule should be used 
only under unusual circumstances and is not recommended 
routinely. The last dose should be administered at least 10 days 
before travel begins to ensure an adequate immune response 
and access to medical care in the event of a delayed adverse 
reaction. The dose is 1.0 mL for persons aged ≥3 years. For 
children aged 1–2 years, the dose is 0.5 mL. The vaccine is not 
licensed for infants aged <1 year.
Recipients should be observed for a minimum of 30 minutes 
after vaccination and warned about the possibility of delayed 
allergic reactions, in particular angioedema of the extremities, 
face or oropharynx, or generalized urticaria. Vaccinees should 
be advised to remain in areas with access to medical care for 10 
days after receiving each dose of JE-MB because of the possibil-
ity of delayed hypersensitivity. The full course of vaccination 
should be completed at least 10 days before travel.
Booster Doses
JE-VC
The need for and timing of booster doses following a 
2-dose primary series with JE-VC has not been determined, 
and further study is needed. The full duration of protection 
following primary vaccination with JE-VC is unknown. One 
immunogenicity study indicated that 95% (172/181) of sub-
jects maintained protective neutralizing antibodies 6 months 
after receiving the first dose and 83% (151/181) still had 
protective antibodies 12 months after primary vaccination 
(164). However, a subsequent study determined that only 83% 
(96/116), 58% (67/116), and 48% (56/116) of subjects had 
protective antibodies at 6, 12, and 24 months after their first 
vaccination, respectively (165). 
JE-MB
The full duration of protection following primary vaccina-
tion with JE-MB also is unknown. However, immunogenicity 
studies indicate that neutralizing antibodies likely persist for at 
least 2 years (175,177–179). A booster dose of 1.0 mL (0.5 mL 
for children aged <3 years) of JE-MB may be administered 2 
BOX 3. Recommendations for the use of Japanese encepha-
litis (JE) vaccine
Recommended
Laboratory workers with a potential for exposure to •	
infectious JE virus (JEV) 
Travelers who plan to spend a month or longer in •	
endemic areas during the JEV transmission season
Consider
Short-term travelers (<1 month) to endemic areas •	
during the JEV transmission season if they plan to 
travel outside of an urban area and have an itiner-
ary or activities that will increase their risk of JEV 
exposure
Travelers to an area with an ongoing JE outbreak•	
Travelers to endemic areas who are uncertain of spe-•	
cific destinations, activities, or duration of travel
Not recommended
Short-term travelers whose visit will be restricted to •	
urban areas or times outside of a well-defined JEV 
transmission season.
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years after the primary series when indicated for planned travel 
or possible laboratory exposure (see Recommendations for 
the Prevention of JE Among Travelers and Recommendations 
for the Use of JE Vaccines in Laboratory Workers. The dura-
tion of immunity after serial booster doses has not been well 
established.
No data exist on the use of JE-VC as a booster dose after a 
primary series with JE-MB. Because of limited supply, remain-
ing doses of JE-MB are being reserved for use in children 
aged 1–16 years. If a booster dose of JE-MB is not available, 
adults aged ≥17 years who have received JE-MB previously 
and require further vaccination against JEV should receive a 
2-dose primary series of JE-VC.
Interchangeability of JE Vaccines
No data exist on the interchangeability of JE-VC and JE-MB 
for use in the primary series or as a booster dose. 
Simultaneous Administration of other 
Vaccines or Drugs 
JE-VC
A clinical trial in which the first dose of JE-VC was admin-
istered concomitantly with hepatitis A vaccine (HAVRIX®) 
indicated no interference with the immune response to JE-VC 
or hepatitis A vaccine (166). Subjects who received concomi-
tant vaccination with JE-VC and hepatitis A vaccine were 
more likely to report pain, redness, and swelling than subjects 
who received either vaccine alone. No other differences were 
reported in safety or reactogenicity with concomitant admin-
istration of JE-VC and hepatitis A vaccine compared with 
administration of each vaccine alone.
No data exist on administration of JE-VC with other vaccines 
or medications. If JE-VC is administered concomitantly with 
other vaccines, they should be given with separate syringes at 
different sites.
JE-MB
Limited data suggest that immunogenicity and safety are 
not compromised when inactivated mouse brain–derived JE 
vaccines, including JE-MB, are administered simultaneously 
with measles-mumps-rubella, diphtheria-tetanus-pertussis or 
oral polio vaccines (206,207). No data exist on the effect of 
concurrent administration of medications or other biologicals 
on the safety and immunogenicity of JE-MB.
Contraindication and Precautions 
for the Use of JE Vaccines
Allergy to Vaccine Components
JE-VC
A severe allergic reaction (e.g., anaphylaxis) after a previ-
ous dose of JE-VC is a contraindication to administration 
of subsequent doses. JE-VC contains protamine sulfate, a 
compound known to cause hypersensitivity reactions in some 
persons (14).
JE-MB
A history of an allergic or hypersensitivity reaction (i.e., 
generalized urticaria and angioedema) to a previous dose of 
JE-MB is a contraindication to receiving additional doses 
(146). Hypersensitivity to thimerosal is a contraindication to 
vaccination, and persons with a proven or suspected hyper-
sensitivity to proteins of rodent or neural origin should not 
receive JE-MB.
Persons with a history of previous allergic reactions or 
urticaria attributed to any cause (e.g., medications, other vac-
cinations, or insect bite) might be at higher risk for allergic 
complications from JE-MB (185,190). This history should be 
considered as a precaution when weighing the risks and benefits 
of the vaccine for an individual patient. When patients with 
such a history are offered JE vaccine, they should be alerted 
to their increased risk for reaction and monitored appropri-
ately. No data exist that support the efficacy of prophylactic 




The safety and effectiveness of JE-VC among children has 
not been established; studies are in progress. Until data are 
available, JE vaccination of children aged 1–16 years should 
be performed with JE-MB.
JE-MB
JE-MB is licensed for use in persons aged ≥1 year. No data 
are available on the safety and efficacy of JE-MB among infants 
aged <1 year. Although other inactivated mouse brain–derived 
JE vaccines have been administered to infants as young as age 6 
months in Japan and Thailand (5,147), vaccination of infants 
traveling to JE-endemic countries should be deferred until 
they are aged ≥1 year.
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Pregnancy
Practitioners should use caution when considering the use of 
JE vaccine in pregnant women. Vaccination with JE vaccines 
usually should be deferred because of a theoretic risk to the 
developing fetus. However, pregnant women who must travel 
to an area in which risk for JE is high should be vaccinated if 





JE-VC is approved for use in persons aged ≥17 years. Data 
are limited on the use of the vaccine in persons aged ≥65 years 
(n = 24) but suggest that safety and immunogenicity are similar 
to that among younger subjects (14). However, further trials 
are needed to determine whether older adults respond differ-
ently than younger subjects. (For information on children aged 
<17 years, see the section on age under Contraindications and 
Precautions for the Use of JE Vaccines).
JE-MB
JE-MB is approved for use in children aged ≥1 year. JE-MB 
remains the only JE vaccine that is approved for use in children 
in the United States. Although JE-MB still is approved for use 
in adults, to conserve supply and help meet the JE vaccine 
needs for children, Sanofi Pasteur has reserved its remaining 
JE-MB inventory for use in children aged 1–16 years. Health-




FDA classifies JE-VC as a “Pregnancy Category B” 
medication. No studies of JE-VC in pregnant women have 
been conducted (14). See the section on pregnancy under 
Contraindications and Precautions for the Use of JE Vaccines 
for more information.
JE-MB
FDA classifies JE-VC as a “Pregnancy Category C” medi-
cation. No specific information is available on the safety of 
JE-MB in pregnancy (146). See the section on pregnancy under 
Contraindications and Precautions for the Use of JE Vaccines 
for more information.
Breastfeeding Women
Breastfeeding is not a contraindication to vaccination. 
However, whether JE-VC or JE-MB is excreted in human milk 
is not known. Because many drugs are excreted in human milk, 
practitioners should use caution when considering the use of 
JE vaccine in breastfeeding women.
Altered Immune States
JE-VC
No data exist on the use of JE-VC in immunocompromised 
persons or patients receiving immunosuppressive therapies.
JE-MB
In limited studies in children infected with HIV or with 
underlying medical conditions including neoplastic disease, 
the safety profile of JE-MB was similar to that in healthy 
children (208–210). A reduced immune response was seen in 
HIV-infected children. However, most children with immune 
recovery after highly active antiretroviral therapy developed a 
protective antibody response (209,210).
Postlicensure Surveillance for 
Vaccine Adverse Events
JE-VC is a promising JE vaccine for travelers given its favor-
able immunogenicity and reactogenicity profile after a 2-dose 
primary series. In addition, because JE-VC does not contain 
gelatin or murine proteins, it might be associated with fewer 
hypersensitivity or neurologic adverse events than the mouse 
brain–derived vaccine. However, the actual cause of these 
reactions following mouse brain–derived vaccine is unknown. 
Because JE-VC has been studied in <5,000 recipients, the 
possibility of these or other rare adverse events cannot be 
excluded. Postlicensure studies and surveillance data from the 
United States, Europe, and Australia will be used to evaluate 
the safety profile of JE-VC in larger populations.
Reporting of Vaccine Adverse 
Events
As with any newly licensed vaccine, surveillance for rare 
adverse events associated with administration of JE vaccine 
is important for assessing its safety in widespread use. Even 
if a causal relation to vaccination is not certain, all clinically 
significant adverse events should be reported to the Vaccine 
Adverse Events Reporting System (VAERS) at http://vaers.
hhs.gov or at telephone 800-822-7967.
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Future Research on JE-VC
Additional studies of JE-VC will be needed to evaluate 
safety and effectiveness further, including children and adults 
aged ≥65 years; duration of protection and need for booster 
doses; the ability of JE-VC to provide an anamnestic immune 
response in persons previously vaccinated with JE-MB; and 
concomitant administration with other travel vaccines or 
medications.
Additional information
Additional information about JE is available from CDC 
at http://www.cdc.gov/ncidod/dvbid/jencephalitis/index.
htm and in CDC’s recommendations for international travel 
(3). Additional licensure information for the two JE vac-
cines approved in the United States is available from FDA 
at http://www.fda.gov/BiologicsBloodVaccines/Vaccines/
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